These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 23461612)

  • 21. Oxidative stress in systemic lupus erythematosus: relationship to Th1 cytokine and disease activity.
    Shah D; Kiran R; Wanchu A; Bhatnagar A
    Immunol Lett; 2010 Mar; 129(1):7-12. PubMed ID: 20105444
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Serum neopterin, tumor necrosis factor-alpha and soluble tumor necrosis factor receptor II (p75) levels and disease activity in Egyptian female patients with systemic lupus erythematosus.
    Mahmoud RA; El-Gendi HI; Ahmed HH
    Clin Biochem; 2005 Feb; 38(2):134-41. PubMed ID: 15642275
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Anti-C1q antibodies and antiendothelial cell antibodies in systemic lupus erythematosus - relationship with disease activity and renal involvement.
    Oelzner P; Deliyska B; Fünfstück R; Hein G; Herrmann D; Stein G
    Clin Rheumatol; 2003 Oct; 22(4-5):271-8. PubMed ID: 14576989
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Concentration of antibodies to extractable nuclear antigens and disease activity in systemic lupus erythematosus.
    Agarwal S; Harper J; Kiely PD
    Lupus; 2009 Apr; 18(5):407-12. PubMed ID: 19318392
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Lymphocytotoxic antibodies in systemic lupus erythematosus are associated with disease activity irrespective of the presence of neuropsychiatric manifestations.
    Magalhães MB; da Silva LM; Voltarelli JC; Donadi EA; Louzada-Junior P
    Scand J Rheumatol; 2007; 36(6):442-7. PubMed ID: 18092265
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Elevated serum anti-endothelial cell autoantibodies titer is associated with lupus nephritis in patients with systemic lupus erythematosus.
    Tseng JC; Lu LY; Hu RJ; Kau CK; Cheng HH; Lin PR; Sun CW; Liang HT; Lam HC; Tai MH
    J Microbiol Immunol Infect; 2007 Feb; 40(1):50-5. PubMed ID: 17332907
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Association of plasma B lymphocyte stimulator levels and disease activity in systemic lupus erythematosus.
    Petri M; Stohl W; Chatham W; McCune WJ; Chevrier M; Ryel J; Recta V; Zhong J; Freimuth W
    Arthritis Rheum; 2008 Aug; 58(8):2453-9. PubMed ID: 18668552
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Vitamin D deficiency as marker for disease activity and damage in systemic lupus erythematosus: a comparison with anti-dsDNA and anti-C1q.
    Mok CC; Birmingham DJ; Ho LY; Hebert LA; Song H; Rovin BH
    Lupus; 2012 Jan; 21(1):36-42. PubMed ID: 21993384
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical significance of nailfold capillaroscopy in systemic lupus erythematosus: correlation with endothelial cell activation markers and disease activity.
    Kuryliszyn-Moskal A; Ciolkiewicz M; Klimiuk PA; Sierakowski S
    Scand J Rheumatol; 2009; 38(1):38-45. PubMed ID: 18991188
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Anti-serum amyloid component P antibodies in patients with systemic lupus erythematosus correlate with disease activity.
    Zandman-Goddard G; Blank M; Langevitz P; Slutsky L; Pras M; Levy Y; Shovman O; Witte T; Doria A; Rovensky J; Shoenfeld Y
    Ann Rheum Dis; 2005 Dec; 64(12):1698-702. PubMed ID: 16014675
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Enhanced recognition of reactive oxygen species damaged human serum albumin by circulating systemic lupus erythematosus autoantibodies.
    Rasheed Z; Ahmad R; Rasheed N; Ali R
    Autoimmunity; 2007 Nov; 40(7):512-20. PubMed ID: 17966041
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Antibodies to apolipoprotein A-I, high-density lipoprotein, and C-reactive protein are associated with disease activity in patients with systemic lupus erythematosus.
    O'Neill SG; Giles I; Lambrianides A; Manson J; D'Cruz D; Schrieber L; March LM; Latchman DS; Isenberg DA; Rahman A
    Arthritis Rheum; 2010 Mar; 62(3):845-54. PubMed ID: 20131231
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Circulating endothelial cells, endothelial apoptosis and soluble markers of endothelial dysfunction in patients with systemic lupus erythematosus-related vasculitis.
    Kluz J; Kopeć W; Jakobsche-Policht U; Adamiec R
    Int Angiol; 2009 Jun; 28(3):192-201. PubMed ID: 19506538
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Angiogenic activity in sera of patients with systemic lupus erythematosus.
    Sakly N; Mirshahi P; Ducros E; Soria J; Ghedira I; Mirshahi M
    Lupus; 2009 Jul; 18(8):705-12. PubMed ID: 19502266
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Negative correlation between fetuin-A and indices of vascular disease in systemic lupus erythematosus patients with and without lupus nephritis.
    Abdel-Wahab AF; Fathy O; Al-Harizy R
    Arab J Nephrol Transplant; 2013 Jan; 6(1):11-20. PubMed ID: 23282228
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Vascular endothelial growth factor in systemic lupus erythematosus: relationship to disease activity, systemic organ manifestation, and nailfold capillaroscopic abnormalities.
    Kuryliszyn-Moskal A; Klimiuk PA; Sierakowski S; Ciołkiewicz M
    Arch Immunol Ther Exp (Warsz); 2007; 55(3):179-85. PubMed ID: 17557150
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Anti-C1q antibodies in nephritis: correlation between titres and renal disease activity and positive predictive value in systemic lupus erythematosus.
    Marto N; Bertolaccini ML; Calabuig E; Hughes GR; Khamashta MA
    Ann Rheum Dis; 2005 Mar; 64(3):444-8. PubMed ID: 15286009
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Phagocyte-specific S100A8/A9 protein levels during disease exacerbations and infections in systemic lupus erythematosus.
    Soyfoo MS; Roth J; Vogl T; Pochet R; Decaux G
    J Rheumatol; 2009 Oct; 36(10):2190-4. PubMed ID: 19755614
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Activation of the interferon-alpha pathway identifies a subgroup of systemic lupus erythematosus patients with distinct serologic features and active disease.
    Kirou KA; Lee C; George S; Louca K; Peterson MG; Crow MK
    Arthritis Rheum; 2005 May; 52(5):1491-503. PubMed ID: 15880830
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Serum albumin as a marker for disease activity in patients with systemic lupus erythematosus.
    Yip J; Aghdassi E; Su J; Lou W; Reich H; Bargman J; Scholey J; Gladman DD; Urowitz MB; Fortin PR
    J Rheumatol; 2010 Aug; 37(8):1667-72. PubMed ID: 20516026
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.